药学学报, 2021, 56(11): 2881-2886
引用本文:
苗洋, 李霄鹤, 翟芸芊, 白佳坤, 马晓阳, 希布日, 张建伟, 周红刚*, 杨诚*. 特发性肺纤维化抗体药物研发进展[J]. 药学学报, 2021, 56(11): 2881-2886.
MIAO Yang, LI Xiao-he, ZHAI Yun-qian, BAI Jia-kun, MA Xiao-yang, XI Bu-ri, ZHANG Jian-wei, ZHOU Hong-gang*, YANG Cheng*. Research and development progress of antibody drugs for idiopathic pulmonary fibrosis[J]. Acta Pharmaceutica Sinica, 2021, 56(11): 2881-2886.

特发性肺纤维化抗体药物研发进展
苗洋, 李霄鹤, 翟芸芊, 白佳坤, 马晓阳, 希布日, 张建伟, 周红刚*, 杨诚*
南开大学药学院, 药物化学生物学国家重点实验室, 天津市分子药物研究重点实验室, 天津 300350
摘要:
特发性肺纤维化是一种纤维化疾病。目前其发病机制尚未被完全阐明,而且没有确切治疗效果的药物用于此疾病。抗体药物经过4个阶段的发展,以其自身优势正成为药物研发的新热点。目前,已有多款药物进入临床试验研究阶段。基于此,本文总结了针对特发性肺纤维化临床试验研究阶段的抗体药物,以期对抗体药物的发展进行总结,为抗体药物的研发提供一定的依据与思路。
关键词:    特发性肺纤维化      发病机制      抗体药物      靶点      临床试验     
Research and development progress of antibody drugs for idiopathic pulmonary fibrosis
MIAO Yang, LI Xiao-he, ZHAI Yun-qian, BAI Jia-kun, MA Xiao-yang, XI Bu-ri, ZHANG Jian-wei, ZHOU Hong-gang*, YANG Cheng*
State Key Lab of Medicinal Chemical Biology, Tianjin Key Lab of Molecular Drug Research, College of Pharmacy, Nankai University, Tianjin 300350, China
Abstract:
Idiopathic pulmonary fibrosis is a fibrous disease. At present, its pathogenesis has not been fully elucidated and there is no drug with definite therapeutic effect. After four stages of development, antibody drugs are becoming a new hotspot in drug research and development with their own advantages. A number of drugs have entered the stage of clinical trials. Based on this, this review summarizes the antibody drugs for the clinical stage of clinical research of idiopathic pulmonary fibrosis, in order to summarize the development of antibody drugs, and provide certain bases and ideas for the development of antibody drugs.
Key words:    idiopathic pulmonary fibrosis    pathogenesis    antibody drug    target    clinical trial   
收稿日期: 2021-02-22
DOI: 10.16438/j.0513-4870.2021-0247
基金项目: 国家自然科学基金资助项目(82070060).
通讯作者: 周红刚,Tel:15022206769,E-mail:honggang.zhou@nankai.edu.cn;杨诚,Tel:15901351388,E-mail:cheng.yang@nankai.edu.cn
Email: honggang.zhou@nankai.edu.cn;cheng.yang@nankai.edu.cn
相关功能
PDF(552KB) Free
打印本文
0
作者相关文章
苗洋  在本刊中的所有文章
李霄鹤  在本刊中的所有文章
翟芸芊  在本刊中的所有文章
白佳坤  在本刊中的所有文章
马晓阳  在本刊中的所有文章
希布日  在本刊中的所有文章
张建伟  在本刊中的所有文章
周红刚*  在本刊中的所有文章
杨诚*  在本刊中的所有文章

参考文献:
[1] Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group[J]. J Intern Med, 2016, 281: 149-166.
[2] Nie LP, Liu GT. New progress in the treatment of idiopathic pulmonary fibrosis[J]. J Clin Pulm Med (临床肺科杂志), 2016, 21: 743-745.
[3] Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guide1ine: treatment of idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2015, 192: e3-e19.
[4] Yang WS, Gao MY, Bai YB, et al. Nanomaterials and biotechnology[M]//Chemical Industry Press 1st Edition (化学工业出版社第1版). Beijing: Chemical Industry Press, 2005: 123.
[5] Thorpe SJ, Turner C, Heath A, et al. Clonal analysis of a human antimouse antibody (HAMA) response[J]. Scand J Immunol, 2003, 57: 85-92.
[6] Buss NA, Henderson SJ, Mcfarlane M, et al. Monoclonal antibody therapeutics: history and future[J]. Curr Opin Pharmacol, 2012, 12: 615-622.
[7] Nelson AL, Dhimole AE, Reichert JM. Development trends for human monoclonal antibody therapeutics[J]. Nat Rev Drug Discov, 2010, 9: 767-774.
[8] Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis[J]. Fibrogenesis Tissue Repair, 2012, 5: S24.
[9] Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial[J]. Lancet Respir Med, 2019. DOI: 10.1016/S2213-2600(19)30262-0.
[10] Raghu G,Brown KK, Collard HR, et al. Efficacy of simtuzumab versus placebo inpatients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial[J]. Lancet Respir Med, 2017, 5: 22-32.
[11] Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production[J]. J Clin Invest, 1999, 103: 779-788.
[12] Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis[J]. Am J Respir Cell Mol Biol, 2002, 27: 419-427.
[13] Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis[J]. J Allergy Clin Immunol, 2015, 135: 500-507.
[14] Clarke DL, Murray LA, Crestani B, et al. Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis[J]. Pharmacol Ther, 2017, 169: 35-46.
[15] Parker JM, Glaspole IN, Lancaster LH, et al. A phase 2 randomized controlled study oftralokinumab in subjects with idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2018, 197: 94-103.
[16] Faffe DS, Whitehead T, Moore PE, et al. IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 285: L907-L914.
[17] Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease[J]. Respirology, 2014, 19: 353-359.
[18] Donahoe M, Valentine VG, Chien N, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis[J]. PLoS One, 2015, 10: e0127771.
[19] Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity[J]. Ann Rheum Dis, 2019, 78: 641-647.
[20] Kolodsick JE, Toews GB, Jakubzick CV, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts[J]. J Immunol, 2004, 172: 4068-4076.
[21] Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. N Engl J Med, 2018, 378: 2486-2496.
[22] Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial[J]. Lancet Respir Med, 2018, 6: 499-510.
[23] Panettieri RA, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS1 and STRATOS2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials[J]. Lancet Respir Med, 2018, 6: 511-525.
[24] Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials[J]. Lancet Respir Med, 2016, 4: 781-796.
[25] Shao RG. Tumor immunotherapy based on monoclonal antibody[J]. Acta Pharm Sin (药学学报), 2020, 55: 1110-1118.
相关文献:
1.陈淑珍, 甄永苏.新型微生物来源的针对不同靶点的抗肿瘤药物研究进展[J]. 药学学报, 2018,53(6): 833-838
2.苗庆芳, 邵荣光, 甄永苏.抗肿瘤抗体药物研究进展[J]. 药学学报, 2012,47(10): 1261-1268